All results from the present study indicate that inhibition of ERK/MAPK signaling pathway activity may indeed reverse MDR in HCC cells, thus providing evidence for the use of ERK/MAPK signaling pathway inhibitors combined with traditional drugs in treating HCC. The gene discussed is MAPK1; the disease is hepatocellular carcinoma.